Showing results (631-640 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|August 10, 2004
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft modelDavid Raben, Cataldo Bianco, Vincenzo Damiano, et al.
Molecular Cancer Therapeutics|April 14, 2004
Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapyAfshin Dowlati, David Nethery, Jeffrey A Kern
Molecular Cancer Therapeutics|April 14, 2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferationMayumi Ono, Akira Hirata, Takuro Kometani, et al.
Molecular Cancer Therapeutics|April 14, 2004
Induction of endoplasmic reticulum stress by ellipticine plant alkaloidsMaria Hägg, Maria Berndtsson, Aleksandra Mandic, et al.
Molecular Cancer Therapeutics|April 14, 2004
Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progressionStephen Swenson, Fritz Costa, Radu Minea, et al.
Molecular Cancer Therapeutics|June 24, 2004
Interstitial gene delivery in human xenograft prostate tumors using titanium metal seedsMira Jung, Yin Zhang, Alexandre Dimtchev, et al.
Molecular Cancer Therapeutics|June 24, 2004
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulationJie Liu, Chengxiu Li, Wei Qu, et al.
Molecular Cancer Therapeutics|June 24, 2004
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cellsAndrea I Loaiza-Pérez, Susan Kenney, Jamie Boswell, et al.
Molecular Cancer Therapeutics|June 24, 2004
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependentJiabin An, Yiping Sun, Myrna Fisher, et al.
Molecular Cancer Therapeutics|June 24, 2004
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motilityMark D Hjelmeland, Anita B Hjelmeland, Sith Sathornsumetee, et al.
Pageof 599